For comments, suggestions
Created with Raphaël 2.1.0 01.11.2016 Filing date 04.06.2018 Validation fee payment 31.10.2018 (A1) Patent application published 18.03.2022 AGEPI application filing date 31.07.2022 (T2) Translation of the validated European patent 26.04.2025 01.11.2025 Valid until 02.11.2026 Renewal fee to be paid until 01.11.2036 Patent will expire on

Patent in force


(210)Number of the EPO application16862773
(220)Filing date of the EPO application2016.11.01
(80)EPO patent specification publication (B)EPB nr. 02/2022, 2022.01.12
(110)EPO patent number3370768
(11)Number of the documentMD 3370768 T2
(21)Number of the applicatione 2018 0896
(71)Name(s) of applicant(s), code of the countryJANSSEN BIOTECH INC., US;
(72)Name(s) of inventor(s), code of the countryVERONA Raluca, US;
POWERS Gordon, US;
SABINS Nina Chi, US;
DEANGELIS Nikki A., US;
SANTULLI-MAROTTO Sandra, US;
WIEHAGEN Karla R., US;
WU Sheng-Jiun, US;
FERRANTE Catherine, US;
UBANI Enrique-Zudaire, US;
(73)Name(s) of owner(s), code of the countryJANSSEN BIOTECH INC., US;
(54)Title of the inventionAntibodies specifically binding pd-1 and their uses
(13)Kind-of-document code T2
(51)International Patent Classification A61K 39/395 (2006.01.01); C12N 15/13 (2006.01.01); C07K 16/18 (2006.01.01); A61P 35/00 (2006.01.01); C07K 16/28 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2018.10.31
(49)Date of publication of the translation of the validated European patent specification2022.07.31
(30)Priority201562250095 P, 2015.11.03, US
(74)Patent attorney(Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova
(86)International applicationPCT/US2016/059833, 2016.11.01
(87)International publicationWO 2017/079112, 2017.05.11
Up
/Inventions/details/3370768